Usage and dosage of Pralsetinib

Pralsetinib (Pralsetinib) is a kinase inhibitor indicated for the treatment of adult patients with fusion-positive non-small cell lung cancer (NSCLC) who have rearrangement during transfection (RET) as detected by a U.S. Food and Drug Administration (FDA)-approved test. It is also indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine therapy, if radioactive iodine is applicable.

Before patients are treated with platinib, it is necessary to determine whether there is RET gene fusion in thyroid cancer or non-small cell lung cancer. The recommended dose of platinib is 400 mg once daily, taken orally on an empty stomach or without food for at least 2 hours before and 1 hour after taking, and treatment is continued until disease progression or unacceptable toxicity. If you forget to take a dose, do not take a double dose and contact your doctor immediately if you experience any serious side effects or discomfort.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.